This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Bristol-Myers Squibb, Karuna plan to refile US antitrust paperwork for deal focused on neuroscience drug

By Ben Brody ( February 6, 2024, 16:47 GMT | Insight) -- Bristol-Myers Squibb and Karuna Therapeutics pulled US antitrust paperwork for their deal and plan to refile on Feb. 12. The $14 billion transaction would boost Bristol-Myers Squibb’s neuroscience portfolio with Karuna’s treatment for schizophrenia expected to hit the market later this year.Bristol-Myers Squibb and Karuna Therapeutics pulled US antitrust paperwork for their deal and plan to refile on February. 12. The $14 billion transaction would boost Bristol-Myers Squibb’s neuroscience portfolio with Karuna’s treatment for schizophrenia expected to hit the market later this year....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login